Multiple Sclerosis Clinical Trials

ASSESS: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg doses administered orally once daily or glatiramer acetate administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Aims: The purpose of this study is to compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod 0.25mg
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH12-289
Funding Source: Novartis
Contact: Please call 847.570.1439 with questions regarding the study.
Open to Enrollment: Yes